Monday, May 17, 2010 at 11:05 a.m. local time (6:05 a.m. EST)
Jupiter, Fla., May 10 /PR Newswire-First Call/ — Dyadic International, Inc. (Pink Sheets: DYAI) (“Dyadic”), a leading-edge early-stage biotechnology company, announced today that its President and Chief Executive Officer, Mark Emalfarb, is scheduled to present at the Rodman & Renshaw 6th Annual Global Healthcare Conference in London, England on Monday, May 17, 2010 at 11:05 a.m. local time (6:05 a.m. EST). Mr. Emalfarb will discuss how Dyadic is applying its proprietary C1 platform technology for producing human antibodies and other high-value therapeutic proteins in addition to its other industrial uses for growth markets such as cellulosic ethanol, pulp & paper, animal feed and starch and alcohol.
The PowerPoint presentation will be accessible after the conference on Dyadic’s website at www.dyadic.com.
Dyadic is a leading-edge early-stage biotechnology company that uses its patented and proprietary technologies to conduct research, development and commercial activities for the discovery, development, manufacture and sale of products and solutions for the bioenergy, industrial enzyme and biopharmaceutical industries. In particular, Dyadic uses its Trichoderma and C1 fungal strains in the production of its industrial enzymes. Dyadic also utilizes an integrated technology platform based on its patented and proprietary C1 fungus which enables the development and large scale manufacture of low cost proteins and enzymes for diverse market opportunities. The C1 platform technology can also be used to screen for the discovery of novel genes and proteins. Dyadic aggressively pursues licensing arrangements and other commercial opportunities to leverage the value of these technologies by providing its partners and collaborators with the benefits of manufacturing and/or utilizing the enzymes which these technologies help produce. Please visit Dyadic’s website atwww.dyadic.com.
CAUTIONARY STATEMENT FOR FORWARD-LOOKING STATEMENTS
Certain statements contained in this press release are forward- looking statements. These forward-looking statements involve risks and uncertainties that could cause Dyadic’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Except as required by law, Dyadic expressly disclaims any intent or obligation to update any forward-looking statements.
Dyadic International, Inc.
Adam J. Morgan
Vice President General Counsel & Business Development